SHAREHOLDERS

Substantial Shareholders’ Interests and Short Positions in Shares and Underlying Shares

So far as the Directors or the chief executive of the Company are aware of, as at 31 December 2023, the Shareholders, who had an interest or short positions in the Shares or underlying Shares which would fall to be disclosed to the Company under provisions of Divisions 2 and 3 in Part XV of the SFO, or which would be required, pursuant to section 336 of the SFO, to be entered in the register referred to therein, were as follows:

Shareholders	Capacity	Number of Shares held	% of Total Issued Shares (Note 1)
Sakai Global Holdings Ltd.   (“Sakai Global”)	Interest of controlled   corporation (Note 2)	4,205,925,735	95.09 (L)
Sakai Private Trust Company   Pte. Ltd.   (“The Sakai Trustee”)	Beneficial owner	1,979,803,846	44.76 (L)
The Sakai Trustee	Interest of controlled   corporation (Note 3)	1,083,743,314	24.50 (L)
The Sakai Trustee	Interest of controlled   corporation (Note 4)	1,142,378,575	25.83 (L)
Lipkco Group Limited   (“LGL”)	Beneficial owner	804,445,667	18.19 (L)
ChenLipKeong Fund Limited   (“CLK Fund”)	Beneficial owner (Note 4)	1,142,378,575	25.83 (L)

Notes:
(1) Based on the Company’s issued share capital of 4,422,990,160 Shares as at 31 December 2023.
(2) Such interests include (i) Shares directly held by The Sakai Trustee, as trustee of a discretionary family trust named The Sakai Trust of which the late Tan Sri Dr Chen Lip Keong (“Dr Chen”), who passed away on 8 December 2023, was the founder; (ii) Shares indirectly held by The Sakai Trustee through ChenLipKeong Capital Limited (“CLK Capital”), LGL and LIPKCO ENTERPRISES LIMITED (“LEL”); and (iii) Shares to be held by CLK Fund (please refer to note 4 below for details). All of CLK Capital, LGL, LEL and CLK Fund are in turn wholly-owned by The Sakai Trustee as the trustee of The Sakai Trust, which is a Jersey law governed discretionary family trust established by the late Dr Chen as settlor for the purposes of succession planning. The Sakai Trustee is entrusted with legal title to the trust assets for the benefit of the late Dr Chen and his family. The Sakai Trustee is in turn wholly-owned by Sakai Global. Hence, Sakai Global is deemed to be interested in the Shares held by The Sakai Trustee. The sole member of Sakai Global was Dr Chen. For further details, please refer to the announcements of the Company dated 22 July 2022 and 12 December 2023, respectively. The Company will make further disclosure if and when appropriate when it is aware of more details in respect of the administration of The Sakai Trust.
(3) Such interests are held by CLK Capital, LGL and LEL, all of which in turn are wholly-owned by The Sakai Trustee. The Sakai Trustee is therefore deemed to be interested in the Shares held by CLK Capital, LGL and LEL in its capacity as the trustee of The Sakai Trust.
(4) Upon the completion of the DBA and the Subscription Agreement on or before 30 September 2029 or such other extended date as is agreed between the parties, these 1,142,378,575 Settlement Shares or such Adjusted Settlement Shares (both as defined in the circular of the Company dated 22 July 2019) for the development funding of the Naga 3 project will be issued to CLK Fund. The Sakai Trustee is deemed to be interested in the Shares which will be held by CLK Fund in the capacity as the trustee of The Sakai Trust, as it holds the entire issued share capital of CLK Fund.
(5) The letter “L” denotes the entity’s long position in the Shares.

Save as disclosed above and so far as the Directors and the chief executive of the Company are aware of, as at 31 December 2023, no other party had an interest or short positions in the Shares or the underlying Shares which would fall to be disclosed to the Company under provisions of Divisions 2 and 3 in Part XV of the SFO, or which would be required, pursuant to section 336 of the SFO, to be entered in the register referred to therein.